Mark W. Hahn

Mr. Hahn joined as Chief Financial Officer in March 2020.

From January 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Mr. Hahn served as CFO of Dova Pharmaceuticals, a US company developing therapeutics for rare diseases, where he was instrumental in raising capital and in the launch of Dova’s first commercial product. From 2010 until its acquisition by Melinta Therapeutics in November 2017, Mr. Hahn was CFO of Cempra where he led the company’s IPO and several subsequent follow-on offerings. Prior to Cempra, Mr. Hahn was the CFO of several other public and private companies. Mr. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.